References
- Sakihara Y, Parving A. Clinical otosclerosis, prevalence estimates and spontaneous progress. Acta Otolaryngol. 1999;119(4):468–472. doi: 10.1080/00016489950181017.
- Podoshin L, Gertner R, Fradis M, et al. Oral contraceptive pills and clinical otosclerosis. Int J Gynaecol Obstet. 1978;15(6):554–555. doi: 10.1002/j.1879-3479.1977.tb00755.x.
- Gristwood RE, Venables WN. Pregnancy and otosclerosis. Clin Otolaryngol Allied Sci. 1983;8(3):205–210. doi: 10.1111/j.1365-2273.1983.tb01428.x.
- Vessey M, Painter R. Oral contraception and ear disease: findings in a large cohort study. Contraception. 2001;63(2):61–63. doi: 10.1016/s0010-7824(01)00176-7.
- Lippy WH, Berenholz LP, Schuring AG, et al. Does pregnancy affect otosclerosis? Laryngoscope. 2005;115(10):1833–1836. doi: 10.1097/01.MLG.0000187573.99335.85.
- Rudic M, Keogh I, Wagner R, et al. The pathophysiology of otosclerosis: review of current research. Hear Res. 2015;330(Pt A):51–56. doi: 10.1016/j.heares.2015.07.014.
- Jacobs I, Bast RC. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989;4(1):1–12. doi: 10.1093/oxfordjournals.humrep.a136832.
- Scholler N, Urban N. CA125 in ovarian cancer. Biomark Med. 2007;1(4):513–523. doi: 10.2217/17520363.1.4.513.
- Galgano MT, Hampton GM, Frierson HJ. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006;19(6):847–853. doi: 10.1038/modpathol.3800612.
- Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005;65(6):2162–2169. doi: 10.1158/0008-5472.CAN-04-3924.
- Bălaşa Vîrzob CR, Cloşca RM, Poenaru M, et al. Otosclerosis under the magnifying glass. Rom J Morphol Embryol. 2023;64(2):189–197. doi: 10.47162/RJME.64.2.09.
- Anniko M, Bernal-Sprekelsen M, Bonkowsky V, et al. Otorhinolaryngology, head and neck surgery. Berlin: Springer-Verlag; 2010.
- Wan J, Wang Y, Cai G, et al. Elevated serum concentrations of HE4 as a novel biomarker of disease severity and renal fibrosis in kidney disease. Oncotarget. 2016;7(42):67748–67759. doi: 10.18632/oncotarget.11682.
- LeBleu VS, Teng Y, O’Connell JT, et al. Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis. Nat Med. 2013;19(2):227–231. doi: 10.1038/nm.2989.
- Ballester B, Milara J, Montero P, et al. MUC16 ıs overexpressed in ıdiopathic pulmonary fibrosis and ınduces fibrotic responses mediated by transforming growth factor-β1 canonical pathway. Int J Mol Sci. 2021;22(12):6502. doi: 10.3390/ijms22126502.
- Zhang M, Zhang Y, Fu J, et al. Serum CA125 levels are decreased in rectal cancer but increased in fibrosis-associated diseases and in most types of cancers. Prog Mol Biol Transl Sci. 2019;162:241–252. doi: 10.1016/bs.pmbts.2018.12.012.
- Hellström I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63(13):3695–3700.
- Plebani M, HE4 Study Group. HE4 in gynecological cancers: report of a European investigators and experts meeting. Clin Chem Lab Med. 2012;50(12):2127–2136. doi: 10.1515/cclm-2012-0373.
- Crompton M, Cadge BA, Ziff JL, et al. The epidemiology of otosclerosis in a british cohort. Otol Neurotol. 2019;40(1):22–30. doi: 10.1097/MAO.0000000000002047.
- Hodge S, Lopez IA, Cronkite A, et al. Dynamic molecular markers of otosclerosis in the human cochlea. Ann Otol Rhinol Laryngol. 2024;133(4):390–399. doi: 10.1177/00034894231225134.
- Schrauwen I, Ealy M, Huentelman MJ, et al. A genome-wide analysis identifies genetic variants in the RELN gene associated with otosclerosis. Am J Hum Genet. 2009;84(3):328–338. doi: 10.1016/j.ajhg.2009.01.023.
- Csomor P, Sziklai I, Karosi T. Controversies in RELN/reelin expression in otosclerosis. Eur Arch Otorhinolaryngol. 2012;269(2):431–440. doi: 10.1007/s00405-011-1653-4.